$GILD News Why Apple exemplifies everything that’s

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 1:03 PM

$GILD News

Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary 12:00 p.m. Today - Zacks.com
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog 11:17 a.m. Today - Zacks.com
ERBA Diagnostics (ERB) in Focus: Stock Up 7% - Tale of the Tape 9:39 a.m. Today - Zacks.com
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog 9:00 a.m. Today - Zacks.com
Stemline Therapeutics (STML) in Focus: Stock Up 12.3% - Tale of the Tape 8:51 a.m. Today - Zacks.com
AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog 6:35 p.m. Sept. 9, 2014 - Zacks.com
Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog 6:20 p.m. Sept. 9, 2014 - Zacks.com
Gilead Sciences' (GILD) CEO Presents at Morgan Stanley Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Gilead Sciences (GILD) Presents at Morgan Stanley Global Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog 4:50 p.m. Sept. 9, 2014 - Zacks.com
Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog 4:45 p.m. Sept. 9, 2014 - Zacks.com
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog 4:25 p.m. Sept. 9, 2014 - Zacks.com
2 Years Of Dividend Growth Investing - 10 Lessons I Have Learned 2:33 p.m. Sept. 9, 2014 - Seeking Alpha
AbbVie Is Betting Big On Infinity Pharmaceuticals But Should You? 12:59 p.m. Sept. 9, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: GE, F, GILD 9:59 a.m. Sept. 9, 2014 - TheStreet.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Achillion - An Options Strategy For A Potential Acquisition 6:07 p.m. Sept. 8, 2014 - Seeking Alpha
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog 6:05 p.m. Sept. 8, 2014 - Zacks.com
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog 6:00 p.m. Sept. 8, 2014 - Zacks.com
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog 5:35 p.m. Sept. 8, 2014 - Zacks.com

Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher 9:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in September 5:00 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fintech Shake-Up: OPay's $4B NYSE IPO Arrival

It's a big day on Wall Street as OPay dives into the NYSE with a hefty market cap of over $4 billion, signaling a major moment for the fintech arena. Oh, how times are shifting! Today marks the debut of OPay under the ticker 'OPAY,' and let me tell you, there's a buzz in the air that could quicken any seasoned trader's pulse. OPay's Big Day: A New Era of Fintech Their...

Tradier Brokerage Data Breach Sparks Legal Probe

Data Breach Drama Hits Tradier Brokerage Picture a broker-dealer like Tradier Brokerage, out in Charlotte, getting its customers' details hanging out there for the world to see. A calamity, courtesy of a cyberattack on their third-party vendor, Etna Software Corp. And we're talking Social Security numbers, tax IDs—emails across Texas and Massachusetts were popping up...

Investigations Target PAG, BRBS, PSNL for Fair Shareholder Deals

Unpacking the Shareholder's Dilemma in Major Transactions Alright, folks, let's dig into this mess with our favorite Wall Street magnifying glass. We've got Penske Automotive Group (NYSE: PAG), Blue Ridge Bankshares (NYSE: BRBS), and Personalis, Inc. (NASDAQ: PSNL) under the spotlight, each locking themselves into deals that might not exactly scream 'fair play' for the...

CapCut's AI Growth Combines Video, Image, and Music Tools

CapCut's Recognition in the Creative AI Space The shift towards comprehensive creative platforms is taking the tech world by storm, and CapCut's latest nod from Software Experts is turning heads in 2026 with its ambitious integration. Touted for its versatility, CapCut serves creative projects that need an amalgamation of video, image, and audio elements. Tackling the...

Runners Hit NYC Streets to Spotlight Liver Disease

From the Heart: Marathon Runners Champion Liver Disease Awareness There’s something raw and powerful about a community uniting to raise awareness for a cause that's touched so many lives. This Sunday, the TCS New York City Marathon becomes more than a race—it transforms into a moving tapestry of human stories, as runners take to the streets to spotlight liver disease...

BioArctic's Moves: Lecanemab Data and Leadership Insights

BioArctic's Power Play: A Two-Pronged Update Ever feel like biotechnology is just a series of chess moves? BioArctic's recent maneuvers in the life sciences game certainly hint at that. First, they've got data brewing on lecanemab—this ain't small beans, folks, not with Alzheimer's disease in the crosshairs. Then there's their Nomination Committee. It’s like shaking...

STARMUS VIII Merges Science and Art for Change

By Riley Hayes Updated Oct 30, 2026 Category News Views 131

STARMUS VIII: Where Science and Art Collide Think about this: you're basking in the Canary Islands' sun, surrounded by Nobel laureates and astronauts while the riffs of Queen's Sir Brian May soar in the air. That's exactly what went down at STARMUS VIII, a week-long celebration of science and art held in Tenerife and La Palma from October 17 to 22, 2026. A jamboree of...

Alignment Healthcare Faces Investigation Over Alleged Fraud

Rough Waters at Alignment Healthcare Not every day we hear about a company sinking its own ship over bookkeeping shenanigans, but here we are. Alignment Healthcare, sitting on Nasdaq under ticker ALHC, is facing the kind of scrutiny that sends shivers down a boardroom's spine. Yeah, Kahn Swick & Foti—those big hitters in securities litigation—have launched an...

CNOOC Limited's 2026 Surge: New Projects, New Heights

Production Peaks and New Discoveries Over in the bustling corridors of oil and gas, CNOOC Limited is making some strong waves. Why? Because they’ve hit historical peaks in production in the first three quarters of 2026. We’re talking about a net production of 593.7 million barrels of oil equivalent. That’s a 2.7% climb from last year. Seems like CNOOC is really...

A+ Federal Credit Union: New Member Incentives Shine

From Honored Beginnings to Today's Accolades Meandering down the memory lane of Texas's own A+ Federal Credit Union (A+FCU), I can't help but notice—this institution has really carved out a niche. In Austin, they're not just another bank. No, sir. For four straight years, A+FCU has been voted the #1 Credit Union in the Best of ATX Awards. Just let that simmer in your...